when the clinical trial involves:

• An unapproved drug or biologic in Canada
• A new use or formulation of an approved product
• New route of administration or dosage regimen
• Combination therapies not previously authorized

Exceptions apply for observational studies and trials using already-approved drugs within labeled use.

CTA Submission Structure and Format

The CTA in Canada is divided into three parts:

• Module 1: Administrative and regional information
• Module 2: Quality (CMC), nonclinical, and clinical overview
• Module 3: Quality data (full CMC dossier)

The submission is made in non-eCTD electronic format (usually PDF files with a Table of Contents), although Health Canada is moving towards full eCTD acceptance in the future.

Sample Table: CTA Modules and Typical Contents

Module	Content	Reviewer
Module 1	Health Canada forms, protocol, IB, ethics info	Clinical Evaluation Division
Module 2	Overviews of CMC, toxicology, clinical plans	Multidisciplinary
Module 3	Drug substance & product specs, stability data	Biologics & Pharmaceutical Quality Divisions

Review Timelines, No Objection Letter, Ethics, and Compliance Best Practices

Review Timeline and the No Objection Letter (NOL)

Once a CTA is submitted, Health Canada follows a 30-day review period. If no deficiencies or safety concerns are identified, the sponsor receives a No Objection Letter (NOL), authorizing initiation of the trial.

If the agency has concerns, a Clarifax (clarification request) is issued. Sponsors must respond within a specified timeline. If the response is satisfactory, the NOL is issued. If not, the CTA may be rejected.

• Standard Review Time: 30 calendar days
• Clock Stop (Clarifax): Sponsor has 2–10 days to respond

Ethics Committee Approval in Parallel

Health Canada requires that all CTA-authorized trials also receive approval from a Research Ethics Board (REB). However, REB review is conducted in parallel with CTA review — not sequentially.

Key ethics-related documents include:

• Informed Consent Form (ICF)
• Patient-facing materials
• Protocol summary
• Investigator qualifications

Each trial site must obtain its own REB approval before enrolling participants, even after the NOL is received.

Common CTA Deficiencies and How to Avoid Them

Health Canada routinely issues Clarifaxes for issues such as:

• Incomplete CMC information (e.g., missing specifications or stability data)
• Protocol inconsistencies
• Ambiguities in risk management or SAE reporting
• Inadequate justification for dose selection

Sponsors should perform pre-submission QA checks and use checklists published by Health Canada to prevent delays.

Additional Considerations for Biologics and Advanced Therapies

Sponsors of cell and gene therapies, vaccines, or other biologics may be subject to additional scrutiny by the Biologics and Genetic Therapies Directorate (BGTD). These applications typically include:

• Additional manufacturing controls
• Viral safety and adventitious agent testing
• Long-term stability protocols

Early communication with BGTD via a pre-CTA meeting is encouraged to align expectations.

Post-CTA Obligations and Amendments

Sponsors must comply with ongoing obligations, including:

• Annual updates to the CTA
• Prompt reporting of Serious Adverse Events (SAEs)
• Notifying Health Canada of amendments or protocol deviations

For major changes (e.g., new dose level, new indication), a CTA-A (CTA Amendment) must be submitted for review and NOL issuance.

Conclusion: Making Your Canadian CTA Successful

Successfully navigating the Canadian CTA process involves more than compiling documentation. It requires careful planning, clarity in scientific communication, alignment with ethics committees, and adherence to Health Canada’s evolving regulatory expectations.

By leveraging submission templates, engaging in early regulatory communication, and conducting internal quality reviews, sponsors can reduce risk and expedite trial startup. The CTA framework in Canada offers predictability and transparency — essential components in a fast-paced clinical development environment.